DOP Session 5


  • 17:30-18:30 Digital Oral Presentation Session 5: Old and new treatment
    Room: C1-M4-5, Hall C, Bella Center
    Chairs: Paolo Gionchetti, Bologna, Italy
    Anne Strik, Amsterdam, The Netherlands
      17:30-17:36 DOP37: Vedolizumab-induced endoscopic remission in anti-TNF exposed and anti-TNF naïve IBD patients: A large single centre experience
    See Presentation Slides here
    B. Verstockt1,2, E. Mertens1, A. Outtier1, G. Van Assche1, 2, S. Vermeire1, 2, M. Ferrante1, 2
    University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium
      17:36-17:42 DOP38: A vedolizumab specific four-gene colonic signature accurately predicting future endoscopic remission in patients with Inflammatory Bowel Disease
    See Presentation Slides here
    B. Verstockt1,2, S. Verstockt3, P. Sudahakar2, 4, 5, J. Dehairs6, H. Blevi2, G. Van Assche1, 2, S. Vermeire1, 2, M. Ferrante1, 2
    University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 3KU Leuven, Department of Human genetics, Laboratory for Complex Genetics, Leuven, Belgium, 4Earlham Institute, Norwich, United Kingdom, 5Quadram Institute, Norwich, Belgium, 6
    Department of Oncology, Laboratory of Lipid Metabolism and Cancer, Leuven, Belgium

      17:42-17:48 DOP39: Safety of combination biologic and anti-rejection therapy post-liver transplantation in patients with Inflammatory Bowel Disease: London Ontario experience
    See Presentation Slides here
    S. Al Draiweesh1, 2, C. Ma1, 3, M. Alkhattabi1, 4, N. Chande1, B. G. Feagan1, 5, J. C. Gregor1, R. Khanna1, P. Marotta1, A. Sandhu1, K. Qumosani1, A. Teriaky1, M. Brahmania1, V. Jairath1, 5
    Western University, Department of Medicine, Division of Gastroenterology, London, Ontario, Canada, 2King Fahad Specialist Hospital, Department of Medicine, Division of Gastroenterology, Dammam, Saudi Arabia, 3University of Calgary, Division of Gastroenterology and Hepatology, Calgary, Alberta, Canada, 4King Abdulaziz University, Department of Medicine, Rabigh, Saudi Arabia, 5Western University, Department of Epidemiology and Biostatistics, London, Ontario, Canada
      17:48-17:54 DOP40: Effectiveness and safety of reference infliximab and biosimilar in Crohn’s Disease: A French equivalence
    See Presentation Slides here
    A. Meyer1, J. Rudant2, J. Drouin2, A. Weill2, F. Carbonnel3, J. Coste2
    Caisse Nationale Assurance Maladie, Paris, France, 2Caisse Nationale de l’Assurance Maladie, Paris, France, 3Hopital Bicetre, Le Kremlin Bicetre, France
      17:54-18:00 DOP41: Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with Ulcerative Colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: Data from the OCTAVE studies
    See Presentation Slides here
    M. Chiorean1, C. Su2, K. Matsuoka3, A. Orlando4, A. J. Thorpe2, C. I. Nduaka2, D. S. Chapman5, D. A. Woodworth2, N. Lawendy2, G. S. Friedman2, R. D. Cohen6
    Virginia Mason Medical Center, Seattle, WA, United States, 2Pfizer Inc, Collegeville, PA, United States, 3Toho University Sakura Medical Center, Sakura, Chiba, Japan, 4University of Palermo, IBD Unit, Palermo, Italy, 5Pfizer Inc, New York, NY, United States, 6University of Chicago Medicine, Chicago, IL, United States
       18:00-18:06 DOP42: Dietary therapies induce rapid response and remission in Active Paediatric Crohn’s Disease
    See Presentation Slides here
    R. Sigall Boneh1,2, J. Van Limbergen3, A. Assa4, R. Shaoul5, E. Wine6, P. Milman7, S. Cohen8, M. Kori9, S. Peleg10, A. On11, H. Shamaly12, L. Abramas1, A. Levine1, 2
    Wolfson Medical Center, Pediatric Gastroenterology, Holon, Israel, 2Tel Aviv University, Tel Aviv, Israel, 3Dalhousie University, Halifax, Canada, 4Schneider Hospital, Petach Tikva, Israel, 5Meyer Hospital, Haifa, Israel, 6University of Alberta, Edmonton, Canada, 7Hadassah Hospital, Jerusalem, Israel, 8Tel Aviv Medical Center, Tel Aviv, Israel, 9Kaplan Hospital, Rehovot, Israel, 10HaEmek Hospital, Afula, Israel, 11Poriah hospital, Tiberias, Israel, 12French Hospital, Nazareth, Israel
       18:06-18:12 DOP43: Long-term efficacy of tofacitinib in patients who received extended induction therapy: Results of the OCTAVE Open study for tofacitinib delayed responders
    See Presentation Slides here
    D. T. Rubin1, M. C. Dubinsky2, M. Lukas3, D. Quirk4, C. I. Nduaka4, E. Maller4, N. Lawendy4, C. Kayhan4, H. Fan4, D. A. Woodworth4, G. Chan4, C. Su4
    University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL, United States, 2Icahn School of Medicine at Mount Sinai Hospital, Department of Pediatrics and Medicine, New York, NY, United States, 3Charles University, Prague, Czech Republic, 4Pfizer Inc, Collegeville, PA, United States
      18:12-18:18 DOP44: Efficacy and safety of tacrolimus in Ulcerative Colitis: A nationwide, multicentric study from GETECCU
    See Presentation Slides here
    I. Rodriguez-Lago1, J. Castro-Poceiro2, A. Fernández-Clotet2, F. Mesonero3, A. López-Sanromán3, A. López-García4, L. Márquez4, A. Clos-Parals5, F. Cañete5, M. Vicuña6, Ó. Nantes6, O. Merino7, V. Matallana Royo8, J. Gordillo9, A. Elorza1, R. Vicente10, M. J. Casanova11, 12, R. Ferreiro-Iglesias13, P. Pérez-Galindo14, J. M. Benítez15, 16, C. Taxonera17, M. J. García García18, E. Martín Arranz19, M. Calafat20, A. Martín-Cardona21, 22, F. Muñoz Núñez23, J. O. Miquel-Cusachs24, E. Sáinz Arnau25, J. P. Gisbert11, Young IBD Group from GETECCU
    1Hospital de Galdakao, Gastroenterology, Galdakao, Spain, 2Hospital Clinic, Gastroenterology, Barcelona, Spain, 3Hospital Universitario Ramón y Cajal, Gastroenterology, Madrid, Spain, 4Hospital del Mar, Gastroenterology, Barcelona, Spain, 5Hospital Universitario Germans Trias i Pujol, Gastroenterology, Badalona, Spain, 6Complejo Hospitalario de Navarra, Gastroenterology, Pamplona, Spain, 7Hospital de Cruces, Gastroenterology, Bilbao, Spain, 8Hospital Universitario Puerta de Hierro, Gastroenterology, Majadahonda, Spain, 9Hospital de la Santa Creu i Sant Pau, Gastroenterology, Barcelona, Spain, 10Hospital Universitario Miguel Servet, Gastroenterology, Zaragoza, Spain, 11Hospital Universitario de La Princesa, Gastroenterology, Madrid, Spain, 12Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain, 13Hospital Clínico Universitario de Santiago de Compostela, Gastroenterology, Santiago de Compostela, Spain, 14Hospital Montecelo, Gastroenterology, Pontevedra, Spain, 15Hospital Universitario Reina Sofía, Gastroenterology, Córdoba, Spain, 16IMIBIC, Córdoba, Spain, 17Hospital Clínico San Carlos, Gastroenterology, Madrid, Spain, 18Hospital Marqués de Valdecilla, Gastroenterology, Santander, Spain, 19Hospital Universitario La Paz, Gastroenterology, Madrid, Spain, 20Hospital Son Llàtzer, Gastroenterology, Palma, Spain, 21Hospital Universitari Mutua Terrassa, Gastroenterology, Terrassa, Spain, 22Centro de Investigación biomédica en red de enfermedades hepáticas y digestivas (CIBERehd), Terrassa, Spain, 23Hospital de Salamanca, Gastroenterology, Salamanca, Spain, 24Hospital Universitario de Girona, Gastroenterology, Girona, Spain, 25Hospital Arnau de Vilanova, Gastroenterology, Lérida, Spain
      18:18-18:24 DOP45: Adequate infliximab exposure during the induction phase is associated with early complete fistula response in patients with Fistulising Crohn’s Disease: A post-hoc analysis of the ACCENT-2 trial
    See Presentation Slides here
    N. Vande Casteele1,2, K. Papamichael3, J. Jeyarajah2, M. T. Osterman4, A. S. Cheifetz3 1University of California San Diego, Department of Medicine, La Jolla, United States, 2Robarts Clinical Trials, Inc., London, Canada, 3Beth-Israel Deaconess Medical Center, Harvard Medical School, Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Boston, United States, 4University of Pennsylvania, Department of Medicine, Perelman School of Medicine, Philadelphia, United States

Digital Oral Presentations
(as of January 2019)

  • DOP Session 1 Advances in IBD pathophysiology
    Room: C1 M1
    Chairs: Javier Gisbert, Madrid, Spain
    Maximilian Waldner, Erlangen, Germany
    DOP Session 2 Mechanisms of intestinal inflammation
    Room: C1 M0
    Chairs: Loris Riccardo Lopetuso, Rome, Italy
    Britta Siegmund, Berlin, Germany
    DOP Session 3 Translational science in IBD
    Room: C1 M2
    Chairs: Peter Bossuyt, Bonheiden, Belgium
    Axel Dignass, Frankfurt, Germany
    DOP Session 4 Practicalities of IBD patient care
    Room: C1 M3
    Chairs: Uri Kopylov, Tel Aviv, Israel
    Fernando Magro, Porto, Portugal
    DOP Session 5 Old and new treatment
    Room: C1 M4-5
    Chairs: Paolo Gionchetti, Bologna, Italy
    Anne Strik, Amsterdam, The Netherlands
  • DOP Session 6 Novel treatments
    Room C1 M4-5
    Chairs: Marc Ferrante, Leuven, Belgium
    Gionata Fiorino, Rome, Italy
    DOP Session 7 Recent advances of biologic therapies
    Room: C1 M3
    Chairs: Filip Baert, Roeselare, Belgium
    Shomron Ben-Horin, Ramat Gan, Israel
    DOP Session 8 Intestinal healing
    Room: C1 M2
    Chairs: Raja Atreya, Erlangen, Germany
    Marietta Iacucci, Birmingham, United Kingdom
    DOP Session 9 Surgery and IBD
    Room: C1 M1
    Chairs: Paulo Kotze, Curitiba, Brazil
    Andre D'Hoore, Leuven, Belgium
    DOP Session 10 Clinical epidemiology
    Room: C1 M0
    Chairs: Stefanos Bonovas, Milan, Italy
    Johan Burisch, Copenhagen, Denmark